Roche Announces $50 Billion Investment in U.S. Pharma and Diagnostics Expansion Over Next Five Years

On April 22 local time, Roche announced,Will Invest $50 Billion in the U.S. Over the Next Five Years. These investments will further strengthen Roche's strong influence in the United States.

Currently, Roche has 13 manufacturing sites and 15 R&D centers in the United States, covering pharmaceuticals and diagnostics businesses. These investments are expected to create over 12,000 new jobs, including nearly 6,500 construction positions, as well as 1,000 jobs from the construction and expansion of facilities.

As part of this investment,Roche to Expand Its Existing Workforce of Over 25,000 Employees Across 24 Manufacturing Sites in Eight U.S. States. This investment will include:

• Expand and upgrade Roche's operations in Kentucky, Indiana, New Jersey, Oregon, and California.Innovative Drug and Diagnostic Product PortfolioProduction and distribution capabilities in the United States;

• Building an Advanced Facility in PennsylvaniaGene Therapy Production Facility；

• Build a 900,000-square-foot production center to support Roche's expandingNext-Generation Weight Loss Drug Portfolio(Specific location to be determined)；

• Building a facility for use in IndianaContinuous Glucose MonitoringThe new production facility;

• Building a new R&D center in Massachusetts for cutting-edge artificial intelligence (AI) Research, and as Roche's newCardiovascular, Renal and Metabolic FieldsR&D EngineerAs a hub;

• Large-scale expansion and upgrade of Roche's existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California.

According to the Roche press release, once all the newly added and expanded production capacities are put into operation,Roche's exports of pharmaceuticals from the U.S. will exceed its imports.At present, its diagnostics division has achieved a surplus in exports from the United States to other countries.

Roche is not the first multinational pharmaceutical company to announce an expansion of its operations in the United States.. April 10，NovartisAnnounced PlanInvest $23 billion in the next five years, for American infrastructure construction, ensuring that all Novartis critical drugs for American patients are produced in the United States.The United States is an important market for Novartis.In the next five years, Novartis is expected to invest nearly US$50 billion in its U.S. operations.

Cover Source: Corporate Logo

Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点，nor does it recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！